L. Camille Bedrosian's Insider Trades & SAST Disclosures
L. Camille Bedrosian's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 12,425 Common Stock done at an average price of $3.5 . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern L. Camille Bedrosian.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 31 Mar 2025 | 12,425 | 194,375 | - | 3.5 | 43,082 | Common Stock |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 206,800 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | L. Camille Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.54 per share. | 02 Dec 2024 | 5,421 | 138,380 | - | 5.5 | 30,007 | Common Stock |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 11,442 | 143,801 | - | 3.2 | 36,559 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 96,910 | 155,243 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 58,333 | 58,333 | - | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 01 Mar 2023 | 3,881 | 46,720 (0%) | 0% | 45.2 | 175,615 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,663 | 50,601 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 14,000 | 47,938 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 01 Mar 2022 | 2,821 | 33,938 (0%) | 0% | 66.6 | 187,935 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.30 per share. | 30 Jan 2022 | 1,657 | 36,759 (0%) | 0% | 66.3 | 109,859 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 81.14 per share. | 14 Oct 2021 | 359 | 38,416 (0%) | 0% | 81.1 | 29,129 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 01 Sep 2021 | 2,500 | 41,275 (0%) | 0% | 55 | 137,500 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,500 | 53,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,500 | 55,500 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 100.18 per share. | 01 Sep 2021 | 2,500 | 38,775 (0%) | 0% | 100.2 | 250,450 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 01 Sep 2021 | 2,500 | 41,275 (0%) | 0% | 55 | 137,500 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 100.03 per share. | 01 Sep 2021 | 2,500 | 38,775 (0%) | 0% | 100.0 | 250,075 | Common Stock |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.67 per share. | 06 May 2021 | 364 | 38,775 (0%) | 0% | 113.7 | 41,376 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 5,000 | 58,000 | - | - | Stock Option | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 109.09 per share. | 15 Apr 2021 | 5,000 | 39,139 (0%) | 0% | 109.1 | 545,450 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 15 Apr 2021 | 5,000 | 44,139 (0%) | 0% | 55 | 275,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 11,000 | 11,000 | - | - | Stock Option (Right o Buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 5,500 | 39,046 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 4,636 | 43,682 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 138.18 per share. | 01 Mar 2021 | 4,543 | 39,139 (0%) | 0% | 138.2 | 627,752 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 140.36 per share. | 30 Jan 2021 | 2,243 | 33,546 (0%) | 0% | 140.4 | 314,827 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 139.18 per share. | 15 Jan 2021 | 25,000 | 35,789 (0%) | 0% | 139.2 | 3,479,500 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 25,000 | 63,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 15 Jan 2021 | 25,000 | 60,789 (0%) | 0% | 55 | 1,375,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 14 Oct 2020 | 262 | 35,789 (0%) | 0% | 88 | 23,056 | Common Stock |
| Crinetics Pharmaceuticals Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Camille L. Bedrosian | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.26 per share. | 06 May 2020 | 249 | 36,051 (0%) | 0% | 66.3 | 16,499 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges